Introduction
Patients with hematological malignancies relapsing after allogeneic hematopoietic cell transplantation (PBSCT) have a poor prognosis with a median survival of 3-4 months without active treatment. 1, 2 To date there is no standard therapeutic approach to relapse after PBSCT. On the basis of the observations that transfusion of donor-derived lymphocytes (donor lymphocyte infusion, DLI) can induce complete chimerism in patients with mixed chimerism after reduced intensity conditioning, 3 and that DLI can induce a significant GvL effect, 4 DLI has been developed as therapeutic approach for the treatment of such cases. Clinical experience shows that DLI is most effective in low proliferating malignancies or after reduction of malignant cells, that is, after chemotherapy.
2,5-9 DLI is most effective in CML in which it can induce long-term remissions in many patients even after hematological relapse. 10 Depending on the indication, DLI should be termed therapeutic or prophylactic, as response and outcome are markedly different (reviewed in ref. 11) . Induction of GvL is associated with induction of GvHD after DLI. [12] [13] [14] Patients developing acute GvHD (aGvHD) after DLI seem to have a better outcome than patients without GvHD. 13 Most centers use the number of CD3 þ cells Â 10 6 /kg recipient body weight to define T-cell doses. A total cell dose of 10 Â 10 6 CD3 þ cells/kg for related donors seems to be safe and effective, 13, 14 but no consensus on the optimal dosage of DLI has yet been reached. 11, 15 G-CSF is routinely used to mobilize CD34-positive hematopoietic stem cells from healthy volunteer donors before leukapheresis. Although cryopreserved DLI has been reported, analyses of efficacy and safety remain anecdotal. [16] [17] [18] The goal of our report is to show that DLI derived from frozen aliquots of the original G-CSF-stimulated grafts is feasible, safe and effective to induce remissions. Safety is defined by a reasonable incidence of severe GvHD and other complications.
Patients and methods

Patients
Individual patient data were retrieved from our electronic database. We searched all consecutive patients who had undergone allogeneic PBSCT from matched unrelated donors at our unit between November 1998 and March 2008. During this period, 121 patients had received DLI from cryopreserved aliquots derived from the original G-CSF-stimulated graft. Small aliquots of lymphocytes were cryopreserved under Good Manufacturing Practice conditions. Allogeneic PBSCT were performed from HLA-identical (HLA A, B: two digit, HLA DRB1, DQB1: four digit) unrelated donors in 93 of 121 cases; 28 cases were transplanted from HLA-different unrelated donors; 11 cases had received a second allogeneic PBSCT. All patients had given their written informed consent to the treatment and the scientific evaluation. Depending on stage and aggressiveness of their disease, patients received follow-up on a regular basis. Indications for allogeneic PBSCT were AML/myelodysplastic syndrome (n ¼ 63/8), ALL (n ¼ 17), lymphoma (n ¼ 13) and multiple myeloma (n ¼ 10) and myeloproliferative syndrome (n ¼ 10). Conditioning regimens used for initial PBSCT were standard high-dose (BU/cyclophosphamide-based, TBI)-based or reduced toxicity conditioning (fludarabin-based plus a combination of alkylating agents, for example, carmustine (BCNU), melphalan, thiotepa). [19] [20] [21] [22] All patients received CyA-based GvHD prophylaxis regimen ( Table 1) . As there is no generally recognized definition of acute and chronic DLI-induced GvHD, it was graded according to standard criteria, 23 clinical manifestation and time of onset after the first DLI.
Statistical analysis
Data were analyzed using SAS statistical software version 9.1. (SAS Institute, Cary, NC, USA). OS times were calculated as time from first DLI to death from any cause. Patients still alive at the last follow-up were considered as censored observations. Estimated OS rates are displayed by means of the Kaplan-Meier method and compared by means of the log-rank test. In addition, Cox proportional hazards regression models were used to evaluate the impact of possible prognostic factors. A multivariate model was constructed using variable selection (backward elimination).
Results
Between November 1998 and March 2008, a total of 121 DLI from cryopreserved lymphocytes collected from the original G-CSF-stimulated graft were performed at our institution. Indications for DLI were hematological relapse (n ¼ 81; 67%), molecular and/or cytogenetic relapse (n ¼ 5; 4%) and mixed chimerism (n ¼ 22; 18%). In total, 13 patients (11%) with a high risk of relapse, based on clinical judgment received prophylactic DLI, for example, second PBSCT for AML or high-risk ALL. Patients received a median of 4 (range 1-14) DLIs; cumulative median cell dose applied was 7.0 Â 10 6 CD3 þ cells/kg (range 0.43-48.85 Â 10 6 ) at average day 204 after allogeneic PBSCT (range 25-2202). DLIs were derived from the original graft without further manipulation (for characteristics of graft see Table 1 ). Median follow-up was 1127 days.
Side effects
DLIs were well tolerated with no acute adverse reactions.
GvHD. A total of 29 of 121 patients (24%) developed aGvHD at median of 24.5 days after first DLI (range 4-76), of which four developed chronic-type GvHD (cGvHD). Overall, 10 patients developed de novo cGvHD at median day 175 after first DLI (range 114-347). aGvHD was mostly mild (Grade I and II; 9 and 8 patients, respectively). In total, 12 patients (9%) developed severe aGVHD (Grade III and IV; 9 and 3 patients). One patient died because of early DLI-induced aGvHD in CR, and one patient died because of aGvHD with confirmed complete donor chimerism. Both patients had received DLI for hematological relapse. Major site of grade I GvHD was skin, followed by gut, mucosa and liver in higher grade GvHD. Overall, 4 patients developed limited cGvHD, and 10 patients developed extensive cGvHD. One patient with cGvHD died in CR. There was no detectable threshold of T-cell number for induction of aGvHD or cGvHD after DLI.
Infection. Five patients died because of fungal, bacterial or viral infections that did not respond to intensive antibiotic, antimycotic or antiviral therapy. None of the five patients had an objective response to DLI.
Response and survival DLI induced CR, complete chimerism or PR in 34 (28%) of the patients. A total of 24 patients (20%) showed disease stabilization and 50 patients (41%) progressed. One patient had persistent aplasia (graft failure) and five patients died before assessment. In total, 79 patients (65%) were alive for 100 days after the first DLI. Median survival after first DLI was 10.4 months (95% confidence interval: 4.4-26.0) (Figure 1 ). Main cause of death was PD in 68 patients.
Response to DLI and survival were independent of underlying disease, gender, mismatch in blood groups, aGvHD after PBSCT or elevated WBC count. Prognosis depended primarily on the indication for DLI; although median survival in 81 patients with hematological relapse was 3.8 months (95% confidence interval 2.6-5.7), patients who were treated with prophylactic DLI or for molecular relapse/mixed chimerism had a superior prognosis. Here, median survival was not reached (Po0.0001) (Figure 2) . Out of 81 patients, 13 (16%) who had received DLI for treatment of hematological relapse responded to DLI compared with 21 out of 40 (53%) patients in the latter group responded to DLI. In univariate Cox regression analyses (Table 2A) , patients with leucopenia (WBCo2000/mL) before DLI (n ¼ 26) had a similarly poor prognosis (median OS 1.8 months (1.0-2.7) vs 26.0 months; Po0.0001) as patients that had to be treated with chemotherapy before DLI (n ¼ 29; median OS 3.2 months (1.7-9.8) vs 16.4 months (8.0-37.2); Po0.0001). Similarly, patients who had peripheral blasts (n ¼ 30) or more than 5% blasts in the BM (n ¼ 27) had a dismal prognosis (median OS 2.4 vs 27.2 months; Po0.0001 and 3.2 vs 13.2 months; Po0.0001, respectively). Elevated LDH (4250 U/L), also associated with a poorer prognosis, compared with patients with normal LDH (median OS 2.7 (1.7-4.9) vs 20.3 (9.8-39.3) months; P ¼ 0.001).
In addition, for patients who received DLIs more than 1 year after the PBSCT (n ¼ 32), median OS was not reached (nr vs 3.8 (2.6-8.6) months; Po0.0001). Patients who had suffered from cGvHD after the initial PBSCT (n ¼ 39) had a better prognosis than the other patients (median OS 39.3 vs 6.6 months; P ¼ 0.0131), whereas history of aGvHD before DLI did not influence survival (Table 2A) . Multivariate Cox regression analyses (Table 2B) identified time from PBSCT (HR 0.26, 95% confidence interval: 0.13-0.53, Po0.0001) and hematological relapse (hazards ratio 8.34, 95% confidence interval: 3.78-18.38, Po0.0001) as main prognostic factors.
Discussion
Reduced intensity conditioning regimens are better tolerated than standard myeloablative regimens but frequently result in early mixed chimerism and a higher risk of relapse. Therefore, different strategies (prophylactic DLI and so on) have been tested. DLI should be administered as early as signs of imminent relapse (i.e., molecular relapse) are detected. Patients with bulky or aggressive disease or Donor lymphocyte infusion from G-CSF-stimulated grafts J Hasskarl et al apparent hematological relapse may benefit from disease reduction before DLI. 8 We have shown that the use of G-CSF-stimulated lymphocytes from cryopreserved aliquots of the original graft is feasible and efficacious. To overcome logistical hurdles for a second leukapheresis from the original donor, and to reduce the time between indication for DLI and actual DLI, we adopted the strategy to cryopreserve small aliquots of the original G-CSF-stimulated graft in case of sufficiently large grafts, as recommended by some registries. As a GMP-certified center all procedures were carried out with the highest safety standards in accordance with the regulatory agencies.
On the basis of on our results, patients benefiting most from DLI are those who were monitored closely to detect early, that is, mixed chimerism or molecular relapse. Although OS of all patients after first DLI was 10.4 months, and was not reached for patients with nonhematological relapse, patients with hematological relapse had a median OS of 3.8 months. As expected for any treatment, patients responding to DLI had a superior prognosis than non-responding patients. The observation that patients with overt hematological relapse have a very poor prognosis is not unexpected. 1, 24 This furthermore stresses the importance of tight monitoring of minimal residual disease, chimerism or molecular relapse and subsequent early DLI. [25] [26] [27] Positive prognostic factors for better survival were development of cGvHD after the initial PBSCT and time from PBSCT. Preexisting cGVHD possibly reflects a more pronounced GvL effect in those patients. 28 Longer time to relapse from PBSCT could also represent a marker for lessaggressive relapse (mixed chimerism, smoldering leukemia and so on) than in patients relapsing earlier, and merely might reflect disease activity. Other parameters identified to predict poor prognosis such as elevated LDH, leucopenia, elevated BM blasts or peripheral blasts and need for chemotherapy before DLI were relevant prognostic factors, but must be interpreted as surrogate parameters for disease activity/hematological relapse. Thus, survival was mainly influenced by the indication for giving DLI.
DLI-induced GvHD was generally mild and well controlled with standard immunosuppressive therapy. In our patient collective, we were unable to identify a predictor for development of GvHD. Of all the patients who had a history of aGvHD or cGvHD before DLI (n ¼ 56, 46%) 17 (30%) developed any kind of GvHD after DLI compared with patients without previous history of GvHD (n ¼ 18; 28%). Overall 14 (12%) patients developed cGvHD after DLI. Only four of them had suffered from cGvHD before DLI. On the basis of our data we cannot classify preexisting GvHD to be a risk factor for development of DLI-induced GvHD. Our approach to use frozen aliquots of donor lymphocytes from the original G-CSF-stimulated grafts seems feasible and might help to improve prognosis because of the ability to intervene early. Retrospective analyses have certain limitations. In our report, confounding variables such as disease stage, clinical performance and changes in therapeutic approaches, for example, in GvHD prophylaxis might have influenced the results. Nevertheless, a recent retrospective analysis of 118 patients receiving fresh DLI who had received DLI for hematological relapse (37%), molecular relapse (44%) and for other reasons (19%) came to a similar conclusion. 24 Similar to our report, patients with hematological relapse had a poorer prognosis than patients with molecular relapse, and response to DLI correlated with non-hematological relapse, cGvHD and late relapse. The overall incidences of aGvHD and cGvHD were slightly higher than in our patient population (41.5 and 33%, respectively).
In summary, our results imply that cryopreserved DLIs from the G-CSF-primed original graft are effective in inducing clinical responses and might be comparable to fresh DLI. With our strategy, undue delay of DLI can be avoided and the extra strain on the donor to undergo a second leukapheresis can be circumvented.
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